Fixed drug eruptions: Incidence, recognition, and avoidance

American Journal of Clinical Dermatology

Volumn 1, Issue 5, 2000, Pages 277-285

  Lee, Ai Young ^a  

^a Eulji General Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG ERUPTION; HUMAN; INCIDENCE; REVIEW;

DRUG ERUPTIONS; HUMANS; INCIDENCE;

EID: 0034279074     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200001050-00003     Document Type: Review

References (79)

1. Arndt KA, Jick H. Rates of cutaneous reactions to drugs. A report from the Boston Collaborative Drug Surveillance Program. JAMA 1976; 235: 918-22
2. Bigby M, Jick S, Jick H, et al. Drag-induced cutaneous reactions. A report from the Boston Collaborative Drug Surveillance Program on 15438 consecutive inpatients, 1975 to 1982. JAMA 1986; 256: 3358-63
3. Kauppinen K, Alanko K. Oral provocation: uses. Semin Dermatol 1989; 8: 187-91
4. Langeland J. Exanthema fixum due to ultraviolet radiation. Acta Derm Venereol 1982; 62: 169-71
5. Del Rio E, Guimaraens D, Aguilar A, et al. Fixed exanthema induced by ultraviolet radiation. Dermatology 1996; 193: 54-5
6. Kelso JM. Fixed food eruption. J Am Acad Dermatol 1996; 35: 638-9
7. Orchard DC, Varigos GA. Fixed drug eruption to tartrazine. Australas J Dermatol 1997; 38: 212-4
8. Yanguas I, Oleaga JM, Gonzalez-Guemes M, et al. Fixed food eruption caused by lentils. J Am Acad Dermatol 1998; 38: 640-1
9. Puavilai S, Choonhakarn C. Drug eruptions in Bangkok: a 1-year study at Ramathibodi Hospital. Int J Dermatol 1998; 37: 747-51
10. Mahboob A, Haroon TS. Drags causing fixed eruptions: a study of 450 cases. Int J Dermatol 1998; 37: 833-8
11. Stubb S, Heikkila H, Kauppinen K. Cutaneous reactions to drags: a series of in-patients during a five-year period. Acta Derm Venereol (Stockh) 1994; 74: 289-91
12. Sharma VK, Dhar S. Clinical pattern of cutaneous drug eruption among children and adolescents in North India. Ped Dermatol 1995; 12: 178-83
13. Hunziker Th, Kunzi U-P, Braunschweig S, et al. Comprehensive hospital drag monitoring (CHDM): adverse skin reactions, a 20-year survey. Allergy 1997; 52: 388-93
14. Bigby M, Stern RS, Arndt KA. Allergic cutaneous reactions to drugs. Prim Care 1989; 16: 713-27
15. Kuligowski ME, Chang A, Rathi R. Multiple fixed drug eruption due to ibuprofen. Contact Dermatitis 1991; 25: 259-60
16. Sehgal VN, Bhattacharya SN. Multiple fixed drug eruption (FDE) following continuous cotrimoxazole (TMP + SMZ) therapy. J Dermatol 1997; 24: 410-1
17. Mizukawa Y, Shiohara T. Fixed drug eruption presenting as erythema dyschromicum perstans: a flare without taking any medications. Dermatology 1998; 197: 383-5
18. Palungwachira P, Palungwachira P. Fixed drug eruption due to atenolol: a case report. J Med Assoc Thai 1999; 82: 1158-61
19. Inserra DW, Camisa C. Erythema multiforme-like fixed drug eruption. Cutis 1989; 44: 223-5
20. Sowden JM, Smith AG. Multifocal fixed drug eruption mimicking erythema multiforme. Clin Exp Dermatol 1990; 15: 387-8
21. Baird BJ, De Villez RL. Widespread bullous fixed drug eruption mimicking toxic epidermal necrolysis. Int J Dermatol 1988; 27: 170-4
22. Sigal-Nahum M, Konqui A, Gaulier A, et al. Linear fixed drug eruption. Br J Dermatol 1988; 118: 849-51
23. Ozkaya-Bayazit E, Baykal C. Trimethoprim-induced linear fixed drug eruption. Br J Dermatol 1997; 137: 1028-9
24. Grosshans E, Marot L. Blaschkitis in adults. Ann Dermatol Venereol 1990; 117: 9-15
25. Guin JD, Haynie LS, Jackson D, et al. Wandering fixed drug eruption: a mucocutaneous reaction to acetaminophen. J Am Acad Dermatol 1987; 17: 399-402
26. Shelley WB, Shelley ED. Nonpigmenting fixed drug eruption as a distinctive reaction pattern: examples caused by sensitivity to pseudoephedrine hydrochloride and tetrahydrozoline. J Am Acad Dermatol 1987; 17: 403-7
27. Benson PM, Giblin WJ, Douglas DM. Transient, nonpigmenting fixed drug eruption caused by radiopaque contrast media. J Am Acad Dermatol 1990; 23: 379-81
28. Dereure O, Guilhou JJ. Nonpigmenting fixed drug eruption: a new case due to betahistine. Dermatology 1996; 193: 248-50
29. Yeo SN, Kang SJ, Lee AY. Nonpigmenting fixed drug eruption to etodolac [in Korean]. Korean J Dermatol 1999; 37 (5): 673-675
30. Roholt NS, Lapiere JC, Traczyk T, et al. A nonscarring sublamina densa bullous drug eruption. J Am Acad Dermatol 1995; 32: 367-71
31. Thankappan TP, Zachariah J. Drag-specific clinical pattern in fixed drug eruptions. Int J Dermatol 1991; 30: 867-70
32. Sharma VK, Dhar S, Gill AN. Drag related involvement of specific sites in fixed eruptions: a statistical evaluation. J Dermatol 1996; 23: 530-4
33. Jain VK, Dixit VB, Archana. Fixed drug eruption of the oral mucous membrane. Ann Dent 1991; 50: 9-11
34. Kanwar AJ, Dhar S, Ghosh S, et al. Mucosal fixed drug eruption. Dermatology 1994; 188: 171
35. Masu S, Seiji M. Pigmentary incontinence in fixed drug eruption. Histologic and electron microscopic findings. J Am Acad Dermatol 1983; 8: 525-32
36. Stritzler C, Kopf AW. Fixed drug eruption caused by 8-chlorotheophylline in Dramamine® with clinical and histologic studies. J Invest Dermatol 1960; 34: 319-30
37. Van Voorhees A, Stenn KS. Histological phases of Bactrim-induced fixed drug eruption. The report of one case. Am J Dermatopathol 1987; 9: 528-32
38. De Dobbeleer G, Achten G. Fixed drug eruption: ultrastructural study of dyskeratotic cells. Br J Dermatol 1977; 96: 239-44
39. Visa K, Kayhko K, Stubb S, et al. Immunocompetent cells of fixed drug eruption. Acta Derm Venereol 1987; 67: 30-5
40. Hindsen M, Christensen OB, Gruic V, et al. Fixed drug eruption: an immunohistochemical investigation of the acute and healing phase. Br J Dermatol 1987; 116: 351-60
41. Komatsu T, Moriya N, Shiohara T. T cell receptor (TCR) repertoire and function of human epidermal T cells: restricted TCR V alpha-V beta genes are utilized by T cells residing in the lesional epidermis in fixed drug eruption. Clin Exp Dermatol 1996; 104: 343-50
42. Teraki Y, Moriya N, Shiohara T. Drug-induced expression of intercellular adhesion molecule-1 on lesional keratinocytes in fixed drug eruption. Am J Pathol 1994; 145: 550-60
43. Shiohara T, Nickoloff BJ, Sagawa Y, et al. Fixed drug eruption. Expression of epidermal keratinocyte intercellular adhesion molecule-1(ICAM-1). Arch Dermatol 1989; 125: 1371-6
44. Yamauchi R, Morita A, Tsuji T. Fixed drug eruption caused by iopamiol, a contrast medium. J Dermatol 1997; 24: 243-5
45. Alanko K, Stubb S, Reitamo S. Topical provocation of fixed drug eruption. Br J Dermatol 1987; 116: 561-7
46. Alanko K. Topical provocation of fixed drug eruption. A study of 30 patients. Contact Dermatitis 1994; 31: 25-7
47. Ozkaya-Bayazit E, Bayazit H, Ozarmagan G. Topical provocation in 27 cases of cotrimoxazole-induced fixed drug eruption. Contact Dermatitis 1999; 41: 185-9
48. Lee AY. Topical provocation in 31 cases of fixed drug eruption: change of causative drugs in 10 years. Contact Dermatitis 1998; 38: 258-60
49. Lee AY, Lee YS. Provocation tests in a chlormezanone-induced fixed drug eruption. DICP 1991; 25: 604-5
50. Watanabe H, Sueki H, Nakada T, et al. Multiple fixed drug eruption caused by iomeprol (lomeron), a nonionic contrast medium. Dermatology 1999; 198: 291-4
51. Gonzalo Garijo MA, Bobadilla Gonzalez P. Cutaneous reaction to naproxen. Allergol Immunopathol (Madr) 1996; 24: 89-92
52. De Barrio M, Tornero P, Prieto A, et al. Recurrent fixed drug eruption caused by citiolone. J Invest Allergol Clin Immunol 1997; 7: 193-4
53. Garcia JC, Torre F, Sanchez M, et al. Fixed drug eruption induced by lidocaine and patch testing. J Invest Allergol Clin Immunol 1997; 7: 127-8
54. Jimenez I, Anton E, Picans I, et al. Fixed drug eruption from amoxycillin. Allergol Immunopathol (Madr) 1997; 25: 247-8
55. Alanko K. Patch testing in cutaneous reactions caused by carbamazepine. Contact Dermatitis 1993; 29: 254-7
56. Navarro JA, Audicana MT, Villas F, et al. Intradermal testing of fixed drug eruption. Allergy 1996; 51: 963-4
57. Rietschel RL, Fowler Jr JF. The role of patch testing. In: Fisher's contact dermatitis. 4th ed. Baltimore: Williams & Wilkins, 1995: 11-32
58. Fujimoto Y, Hayakawa R, Suzuki M, et al. Fixed drug eruption due to allylisopropylacetylurea. Contact Dermatitis 1993; 28: 282-4
59. Smola H, Kruppa A, Hunzelmann N, et al. Identification of dimenhydrinate as the causative agent in fixed drug eruption using patch-testing in previously affected skin. Br J Dermatol 1998; 138: 920-1
60. Bruynzeel DP, Maibach HI. Patch testing in systemic drug eruptions. Clin Dermatol 1997; 15: 479-84
61. Gomez B, Sastre J, Azofra J, et al. Fixed drug eruption. Allergol Immunopathol (Madr) 1985; 13: 87-91
62. Kauppinen K, Kariniemi A-L. Clinical manifestations and histological characteristics. In: Kauppinen K, Alanko K, Hannuksela M, et al., editors. Skin reactions to drags. Boca Raton: CRC Press, 1998: 30-1
63. Sehgal VN, Rege VL, Kharangate VN. Fixed drug eruption caused by medications: a report from India. Int J Dermatol 1978; 7: 78-81
64. Kanwar AJ, Bharija SC, Singh M, et al. Ninety eight fixed drug eruptions with provocation tests. Dermatologica 1988; 177: 274-9
65. Bharija SC, Belhaj MS. Fixed drug eruption due to cotrimoxazole. Australas J Dermatol 1989; 30: 43-44
66. Morelli JG, Tay Y-K, Rogers M, et al. Fixed drug eruptions in children. J Pediatr 1999; 134: 365-7
67. Alanko K, Stubb S, Kauppinen K. Cutaneous drug reactions: clinical types and causative agents. A five-year survey of in-patients (1981-1985). Acta Derm Venereol (Stockh) 1989; 69: 223-6
68. Sehgal VN, Gangwani OP. Fixed drug eruption. Current concepts. Int J Dermatol 1987; 26: 67-74
69. Browne SG. Fixed eruption in deeply pigmented subjects: clinical observations on 350 patients. BMJ 1964; 2: 1041-4
70. Tham SN, Kwok YK, Chan HL. Cross-reactivity in fixed drug eruptions to tetracyclines. Arch Dermatol 1996; 132: 1134-5
71. Bargman H. Lack of cross-sensitivity between tetracycline, doxycycline, and minocycline with regard to fixed drug sensitivity to tetracycline. J Am Acad Dermatol 1984; 11: 900-1
72. Ordoqui E, De Barrio M, Rodriguez VM, et al. Cross-sensitivity among oxicams in piroxicam-caused fixed drug eruption: two case reports. Allergy 1995; 50: 741-4
73. Mishra D, Mobashir M, Zaheer MS. Fixed drug eruption and cross-reactivity between tinidazole and metronidazole. Int J Dermatol 1990; 29: 740
74. Thami GP, Kanwan AJ. Fixed drug eruption due to metronidazole and tinidazole without cross-sensitivity to secnidazole. Dermatology 1998; 196: 368
75. Pasricha JS, Shukla SS. Independent lesions of fixed eruption due to two unrelated drugs in the same patient. Br J Dermatol 1979; 101: 361-2
76. Chan HL, Tan KC. Fixed drug eruption to three anticonvulsant drugs: an unusual case of polysensitivity. J Am Acad Dermatol 1997; 36: 259
77. Bhargava P, Kuldeep CM, Mathur NK. Polysensitivity and familial occurrence in fixed drug eruption. Int J Dermatol 1997; 36: 236
78. Kelso JM, Keating RM. Successful desensitization for treatment of a fixed drug eruption to allopurinol. J Allergy Clin Immunol 1996; 97: 1171-2
79. Umpierrez A, Cuesta-Herranz J, De Las Heras M, et al. Successful desensitization of a fixed drug eruption caused by allopurinol. J Allergy Clin Immunol 1998; 101: 286-7